2022年11月26日

亚特兰大医疗公司特许经营权医疗系列提出了2000万美元的资金由医疗、特许经营权Inc .)、医疗设备业务开发一个革命性的经导管二尖瓣置换技术,宣布了2000万美元完成一轮融资。Vensana资本和一个广泛的全球医疗器械公司领导,与Epidarex资本、大视野出版社企业和乔治亚研究联盟风险基金也参与。募集资金将支持的特许技术通过早期临床试验的可行性。正在开发一个特许经导管设备(CARLEN)改变本机二尖瓣传单使用独特的植入矫正不足,可能导致二尖瓣返流,同时保留生理阀门形状。“我们现在知道,纠正心力衰竭患者的二尖瓣返流可以减少死亡率和住院率,与早期干预产生最好的结果,“说Murali Padala博士的发明者CARLEN,凯雷弗雷泽心胸埃默里大学的研究实验室主任,和特许经营权医学的创始人。埃里克·l·萨林,医学博士,该公司创始人之一:“经导管治疗可能提高有效性和安全性,同时保持简单是结构性心脏病治疗的“圣杯”。特许经营权团队认可这个事实,设计一个优雅的装置,满足大量的当前需求在治疗心脏瓣膜病。“Amrinder辛格,Vensana资本负责人,说:”的经导管二尖瓣修复市场仍处于初期阶段,许多扩张的可能性。特许经营权的技术提供了一个优雅的治疗选择,是一个合乎逻辑的下一步的进展catheter-based提出治疗二尖瓣返流。我们的团队和临床顾问非常兴奋CARLEN治疗二尖瓣疾病的潜力。 With this fresh round of funding, Nyra has appointed Lisa Wipperman Heine as an independent director to its board of directors. Lisa is a seasoned medical technology professional with over 25 years of experience in operational, management, and board positions. She was most recently the CEO of preCARDIA. Before that, she was the COO of Mitralign and held several leadership positions at Covidien, including Global Vice President of Medical Affairs for Vascular Therapies. More about the company: With the motto ” Simplifying transcatheter repair of heart valves…one valve at a time,” Nyra Medical is a medical device company that develops the CARLEN technology, the transcatheter technology for the treatment of mitral regurgitation. CARLEN help preserves the natural valve form while restoring function, eliminates the potential of stenosis, and preserves future transcatheter and surgical therapy options. We try our best to fact-check and bring the best, well-researched, and non-plagiarized content to you. Please let us know -if there are any discrepancies in any of our published stories, -how we can improve, -what stories you would like us to cover and what information you are looking for, in the comments section below or through our contact form! We look forward to your feedback, and thank you for stopping by!